AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28110513 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (MNTX)
Number of subjects: 15
Study 28110513 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (NA)
Number of subjects: 15
Study 28110513 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 15
Study 25278093 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet
Number of subjects: 47
Study 25278093 — intervention group
Group type: COMPARATOR
Intervention: Regular-sodium diet
Number of subjects: 47
Study 23445141 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg b.d.
Number of subjects: 35
Study 23445141 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg o.d.
Number of subjects: 35
Study 21569613 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental illness vignette (N = 356)
Number of subjects: 654
Study 21569613 — intervention group
Group type: COMPARATOR
Intervention: Diabetes vignette (N = 298)
Number of subjects: 654
Study 19527321 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (doses >= 2.5 mg)
Number of subjects: 0
Study 19527321 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (doses >= 5 mg in non-obese and >= 2.5 mg in obese patients)
Number of subjects: 0
Study 19527321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16432390 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented exercise program with altered sensory input
Number of subjects: 16
Study 16432390 — intervention group
Group type: COMPARATOR
Intervention: Task-oriented exercise program without altered sensory input (control group)
Number of subjects: 16
Study 15097035 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily omeprazole (1 x 20 mg)
Number of subjects: 15
Study 15097035 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily omeprazole (2 x 20 mg)
Number of subjects: 15
Study 15097035 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no treatment)
Number of subjects: 15
Study 11147927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (initial dose 50 mg, titration up to 100 mg)
Number of subjects: 240
Study 11147927 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (75 mg, up to 150 mg)
Number of subjects: 240
Study 9496203 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body cooling (approximately 31 degrees C) during cardiopulmonary bypass
Number of subjects: 26
Study 9496203 — intervention group
Group type: COMPARATOR
Intervention: Warm stimulation (approximately 36 degrees C) during cardiopulmonary bypass
Number of subjects: 26
Study 8468314 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam sustained release, N = 89, treatment duration 4 weeks
Number of subjects: 180
Study 8468314 — intervention group
Group type: COMPARATOR
Intervention: Placebo, N = 91, treatment duration 4 weeks
Number of subjects: 180
Study 8468314 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent MD history
Number of subjects: 180
Study 3101636 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg per tablet, 3 tablets a day for one month)
Number of subjects: 32
Study 3101636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31970593 — intervention group
Group type: EXPERIMENTAL
Intervention: Dotinurad (0.5 mg/day, titrated to 2 mg/day)
Number of subjects: 203
Study 31970593 — intervention group
Group type: COMPARATOR
Intervention: Febuxostat (10 mg/day, titrated to 40 mg/day)
Number of subjects: 203
Study 30143441 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green dye with near-infrared fluorescence imaging
Number of subjects: 180
Study 30143441 — intervention group
Group type: COMPARATOR
Intervention: Isosulfan blue dye
Number of subjects: 180
Study 26432571 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue statin medications
Number of subjects: 244
Study 26432571 — intervention group
Group type: COMPARATOR
Intervention: Discontinue statin medications
Number of subjects: 244
Study 24872333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftiofur crystalline‐free acid (CCFA) administered to all steers in a pen
Number of subjects: 176
Study 24872333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftiofur crystalline‐free acid (CCFA) administered to one steer in a pen
Number of subjects: 176
Study 24872333 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlortetracycline administration after CCFA treatment
Number of subjects: 176
Study 22354772 — intervention group
Group type: COMPARATOR
Intervention: Conventional pulmonary vein isolation (CPVI)
Number of subjects: 185
Study 22354772 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-electrode ablation (MEA)
Number of subjects: 185
Study 20015599 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH) 72mg
Number of subjects: 24
Study 20015599 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 24
Study 20015599 — intervention group
Group type: COMPARATOR
Intervention: Both groups (MPH and PL)
Number of subjects: 24
Study 18352852 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 15962644 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine 300 microg (n = 25)
Number of subjects: 50
Study 15962644 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 25)
Number of subjects: 50
Study 12699020 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard parent-child interaction therapy (PCIT; STD)
Number of subjects: 54
Study 12699020 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified PCIT (abbreviated treatment)
Number of subjects: 54
Study 12699020 — intervention group
Group type: COMPARATOR
Intervention: No-treatment waitlist control group (WL)
Number of subjects: 54
Study 11397498 — intervention group
Group type: EXPERIMENTAL
Intervention: Active participation of mothers during speech therapy sessions
Number of subjects: 59
Study 11397498 — intervention group
Group type: COMPARATOR
Intervention: Control group with no active participation of mothers
Number of subjects: 59
Study 9506597 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke unit
Number of subjects: 550
Study 9506597 — intervention group
Group type: COMPARATOR
Intervention: General medical ward
Number of subjects: 550
Study 8198909 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 99
Study 8198909 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 99
Study 8198909 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 99
Study 8198909 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 99
Study 8198909 — intervention group
Group type: COMPARATOR
Intervention: All groups (Halothane, Enflurane, Isoflurane, Propofol)
Number of subjects: 99
Study 3116071 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline sulfate
Number of subjects: 15
Study 3116071 — intervention group
Group type: EXPERIMENTAL
Intervention: nitroglycerin
Number of subjects: 15
Study 3116071 — intervention group
Group type: EXPERIMENTAL
Intervention: aminophylline
Number of subjects: 15
Study 3116071 — intervention group
Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 15
Study 31060529 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 48
Study 31060529 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 48
Study 28333093 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 g/day dry-cured pork ham
Number of subjects: 38
Study 28333093 — intervention group
Group type: COMPARATOR
Intervention: 100 g/day cooked ham (control product)
Number of subjects: 38
Study 25049068 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo enteric-coated mycophenolate sodium (MPS)
Number of subjects: 164
Study 25049068 — intervention group
Group type: COMPARATOR
Intervention: Delayed-onset everolimus (RAD)
Number of subjects: 164
Study 25049068 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS
Number of subjects: 164
Study 25049068 — intervention group
Group type: COMPARATOR
Intervention: RAD
Number of subjects: 164
Study 24130005 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Alagebrium (200 mg/d)
Number of subjects: 62
Study 24130005 — intervention group
Group type: COMPARATOR
Intervention: Sedentary + Alagebrium (200 mg/d)
Number of subjects: 62
Study 24130005 — intervention group
Group type: COMPARATOR
Intervention: Exercise + Placebo
Number of subjects: 62
Study 24130005 — intervention group
Group type: COMPARATOR
Intervention: Sedentary + Placebo
Number of subjects: 62
Study 20814338 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief parenting discussion group (2-hour session with follow-up calls)
Number of subjects: 67
Study 20814338 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 67
Study 19938212 — intervention group
Group type: EXPERIMENTAL
Intervention: Real intradermal acupuncture (RA group)
Number of subjects: 52
Study 19938212 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA group)
Number of subjects: 52
Study 17040007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal overdrive pacing (NOP) at 75 bpm
Number of subjects: 19
Study 17040007 — intervention group
Group type: COMPARATOR
Intervention: Control at 45 bpm
Number of subjects: 19
Study 17040007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal overdrive pacing (NOP)
Number of subjects: 19
Study 15457450 — intervention group
Group type: COMPARATOR
Intervention: 18-30 year old group
Number of subjects: 30
Study 15457450 — intervention group
Group type: COMPARATOR
Intervention: 66-86 year old group
Number of subjects: 30
Study 10994920 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Back-Saver Sit-and-Reach (MBS) test
Number of subjects: 158
Study 10994920 — intervention group
Group type: COMPARATOR
Intervention: Classical Sit-and-Reach (CSR) test
Number of subjects: 158
Study 10994920 — intervention group
Group type: COMPARATOR
Intervention: Back-Saver Sit-and-Reach (BS) test
Number of subjects: 158
Study 10994920 — intervention group
Group type: COMPARATOR
Intervention: V Sit-and-Reach (VSR) test
Number of subjects: 158
Study 9478258 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification of patients based on origin of coma, duration of stay, future evolution, and cost of treatment.
Number of subjects: 515
Study 8419869 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid mouthwash (5% solution)
Number of subjects: 30
Study 8419869 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (control group)
Number of subjects: 30
Study 31329402 — intervention group
Group type: EXPERIMENTAL
Intervention: ETCS
Number of subjects: 52
Study 31329402 — intervention group
Group type: EXPERIMENTAL
Intervention: ETCS + AHA-Ret
Number of subjects: 52
Study 28569449 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective enamel etching
Number of subjects: 75
Study 28569449 — intervention group
Group type: COMPARATOR
Intervention: Self-etching approach
Number of subjects: 75
Study 25709685 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dialysate sodium
Number of subjects: 0
Study 25709685 — intervention group
Group type: COMPARATOR
Intervention: Stepwise sodium profile
Number of subjects: 0
Study 23158477 — intervention group
Group type: COMPARATOR
Intervention: Alternative sequence (ALT)
Number of subjects: 22
Study 23158477 — intervention group
Group type: COMPARATOR
Intervention: ERC 2005 and ERC 2010 guidelines
Number of subjects: 22
Study 19551502 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support services
Number of subjects: 0
Study 19551502 — intervention group
Group type: COMPARATOR
Intervention: Community mental health services (Control)
Number of subjects: 0
Study 18303382 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 48
Study 18303382 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 48
Study 18303382 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Number of subjects: 48
Study 16527792 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 72
Study 16527792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 14563605 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) using an estro-progestin association (estradiol + a progestin compound), given continuously or with a 5-day interruption each month, mean duration of treatment 2.5 years.
Number of subjects: 230
Study 14563605 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without HRT)
Number of subjects: 230
Study 10715359 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 26
Study 10715359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8956394 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg ketorolac added to the lidocaine used for IVRA
Number of subjects: 60
Study 8956394 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg ketorolac added to the lidocaine used for wound infiltration
Number of subjects: 60
Study 8956394 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional medications)
Number of subjects: 60
Study 1347237 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 (30 mg/kg)
Number of subjects: 20
Study 1347237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3896019 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral cutaneous nerve block
Number of subjects: 0
Study 3896019 — intervention group
Group type: COMPARATOR
Intervention: No block (Control)
Number of subjects: 0
Study 31429601 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy‐Adolescent Skills Training (IPT‐AST)
Number of subjects: 186
Study 31429601 — intervention group
Group type: COMPARATOR
Intervention: Group Counseling (GC)
Number of subjects: 186
Study 29934667 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (TLV) ≤ 15 mg/day
Number of subjects: 81
Study 29934667 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (FUR) ≤ 40 mg/day
Number of subjects: 81
Study 27824375 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided ablation
Number of subjects: 68
Study 27824375 — intervention group
Group type: COMPARATOR
Intervention: Topography-guided ablation
Number of subjects: 68
Study 25064436 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA and percutaneous iodine‐125 seed implantation (RFA‐(125)I)
Number of subjects: 136
Study 25064436 — intervention group
Group type: COMPARATOR
Intervention: RFA‐only
Number of subjects: 136
Study 22508022 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit group (n=11)
Number of subjects: 32
Study 22508022 — intervention group
Group type: EXPERIMENTAL
Intervention: Matter of Balance Group (n=11)
Number of subjects: 32
Study 22508022 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 32
Study 19643946 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month conditioning programme (3 hours of sports per week)
Number of subjects: 38
Study 17039794 — intervention group
Group type: EXPERIMENTAL
Intervention: Batroxobin (0.5 ml, 2 BU/ml)
Number of subjects: 156
Study 17039794 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (2 mg/ml)
Number of subjects: 156
Study 17039794 — intervention group
Group type: EXPERIMENTAL
Intervention: Batroxobin and Dexamethasone
Number of subjects: 156
Study 14702587 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management intervention (two weight management programs and usual care)
Number of subjects: 189
Study 14702587 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies (partnering with community health centers, positive reinforcement, social supportiveness, monitoring progress, free transportation)
Number of subjects: 189
Study 11641593 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubeluzole (7.5 mg i.v. over 1 h, then continuous 5‐day infusion of 10 mg/day)
Number of subjects: 89
Study 11641593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 9207368 — intervention group
Group type: EXPERIMENTAL
Intervention: Peru-15 vaccine (10^7 or 10^9 cfu) in inpatient volunteers
Number of subjects: 62
Study 9207368 — intervention group
Group type: EXPERIMENTAL
Intervention: Peru-15 vaccine (10^8 or 10^9 cfu) in outpatient volunteers
Number of subjects: 62
Study 9207368 — intervention group
Group type: COMPARATOR
Intervention: Placebo in outpatient volunteers
Number of subjects: 62
Study 9207368 — intervention group
Group type: EXPERIMENTAL
Intervention: Peru-15 vaccine (all doses)
Number of subjects: 62
Study 8110249 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-hour transdermal nicotine patch
Number of subjects: 220
Study 8110249 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 220
Study 3625405 — intervention group
Group type: EXPERIMENTAL
Intervention: Steel cannulas
Number of subjects: 151
Study 3625405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous medication administration
Number of subjects: 151
Study 3625405 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition solutions
Number of subjects: 151
Study 3625405 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing cannula gauge
Number of subjects: 151
Study 3625405 — intervention group
Group type: COMPARATOR
Intervention: Gravity-controlled infusion device delivery
Number of subjects: 151
Study 3625405 — intervention group
Group type: COMPARATOR
Intervention: Potassium concentrations less than or equal to 20 mEq/L
Number of subjects: 151
Study 30367723 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone plus deproteinized bovine bone mineral (DBBM) with collagen membrane (Control)
Number of subjects: 48
Study 30367723 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried bone allograft (FDBA) with collagen membrane (Test)
Number of subjects: 48
Study 28670823 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV/cytology cotesting (intervention group)
Number of subjects: 773
Study 28670823 — intervention group
Group type: COMPARATOR
Intervention: Cytology-only (control group)
Number of subjects: 773
Study 27434314 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once-monthly (PP1M) injectable
Number of subjects: 0
Study 27434314 — intervention group
Group type: COMPARATOR
Intervention: Oral paliperidone extended-release (ER)
Number of subjects: 0
Study 25059094 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 80
Study 21890583 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.7 g/kg males; 0.63 g/kg females)
Number of subjects: 90
Study 21890583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 21890583 — intervention group
Group type: COMPARATOR
Intervention: Soft drink
Number of subjects: 90
Study 21890583 — intervention group
Group type: COMPARATOR
Intervention: Threat before Drink, Threat after Drink, No-Threat Control
Number of subjects: 90
Study 21890583 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol problems severity
Number of subjects: 90
Study 19216597 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly filled (58%) resin sealants applied to incisors and canines
Number of subjects: 60
Study 19216597 — intervention group
Group type: COMPARATOR
Intervention: No sealant (control group) applied to contralateral teeth
Number of subjects: 60
Study 19216597 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAGNOdent measurements for sealed teeth
Number of subjects: 60
Study 19216597 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAGNOdent measurements excluding 28 teeth with visible lesions
Number of subjects: 60
Study 17290029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (titrated to 45 mg)
Number of subjects: 5238
Study 16084051 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional surgery combined with 5‐fluorouracil and leucovorin, or irinotecan
Number of subjects: 50
Study 16084051 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery and systemic chemotherapy
Number of subjects: 50
Study 12370501 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (4.5 x 10(6) IU subcutaneously twice daily for 5 days every 6 weeks)
Number of subjects: 72
Study 12370501 — intervention group
Group type: COMPARATOR
Intervention: Control group (HAART alone)
Number of subjects: 72
Study 12370501 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Number of subjects: 72
Study 10507377 — intervention group
Group type: EXPERIMENTAL
Intervention: SSEP with bilaterally normal CCT
Number of subjects: 105
Study 10507377 — intervention group
Group type: EXPERIMENTAL
Intervention: SSEP with any delay in CCT
Number of subjects: 105
Study 10507377 — intervention group
Group type: EXPERIMENTAL
Intervention: SSEP with unilateral absence of cortical component
Number of subjects: 105
Study 10507377 — intervention group
Group type: EXPERIMENTAL
Intervention: SSEP with bilateral absence of cortical component
Number of subjects: 105
Study 8567827 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 5 mg mifepristone
Number of subjects: 17
Study 8567827 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose of 5 mg/day for 3 days (starting when leading follicle was 14-16 mm)
Number of subjects: 17
Study 8567827 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose of 5 mg/day for 3 days (starting when leading follicle was 6-11 mm)
Number of subjects: 17
Study 8567827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2257796 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1000 mg)
Number of subjects: 0
Study 2257796 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid (1000 mg)
Number of subjects: 0
Study 2257796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6159957 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG and 5‐fluorouracil
Number of subjects: 78
Study 6159957 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil
Number of subjects: 78
Study 6159957 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment after palliative resection
Number of subjects: 78
Study 30810703 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotus valve
Number of subjects: 912
Study 30810703 — intervention group
Group type: COMPARATOR
Intervention: CoreValve
Number of subjects: 912